Paul Clarke
机构: Institute of Cancer Research
每年引用次数
引用次数
引用: 16,583
H-指数: 56
I10-指数 : 96
出版物: 215
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Steven R. Whittaker , Aurélie Mallinger , Paul Workman , Paul A. Clarke
Pharmacology & Therapeutics 173 83 -105
271
2017
Discovery of potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19
Aurélie Mallinger , Kai Schiemann , Christian Rink , Frank Stieber
Journal of Medicinal Chemistry 59 ( 3) 1078 -1101
103
2016
Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening
Paul Czodrowski , Aurélie Mallinger , Dirk Wienke , Christina Esdar
Journal of Medicinal Chemistry 59 ( 20) 9337 -9349
51
2016
The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy
Nada M.S. Al-Saffar , L. Elizabeth Jackson , Florence I. Raynaud , Paul A. Clarke
Cancer Research 70 ( 13) 5507 -5517
57
2010
Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Paul Workman , Paul A. Clarke , Florence I. Raynaud , Rob L.M. van Montfort
Cancer Research 70 ( 6) 2146 -2157
228
2010
De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder.
Eduardo Calpena , Alexia Hervieu , Teresa Kaserer , Sigrid M.A. Swagemakers
American Journal of Human Genetics 104 ( 4) 709 -720
37
2019
The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design
Sylvain Couty , Isaac M. Westwood , Andrew Kalusa , Celine Cano
Oncotarget 4 ( 10) 1647 -1661
15
2013
Ketone-directed peracid epoxidation of cyclic alkenes
Alan Armstrong , Paul A. Barsanti , Paul A. Clarke , Anthony Wood
Journal of The Chemical Society-perkin Transactions 1 ( 12) 1373 -1380
6
1996
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Richard D. Baird , Jos Kitzen , Paul A. Clarke , Andre Planting
Molecular Cancer Therapeutics 8 ( 6) 1430 -1437
36
2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud , Suzanne A. Eccles , Sonal Patel , Sonia Alix
Molecular Cancer Therapeutics 8 ( 7) 1725 -1738
224
2009
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Craig P. Carden , Adam Stewart , Parames Thavasu , Emma Kipps
Molecular Cancer Therapeutics 11 ( 7) 1609 -1617
62
2012
Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential
Paul A. Clarke , Robert te Poele , Richard Wooster , Paul Workman
Biochemical Pharmacology 62 ( 10) 1311 -1336
270
2001
Correlation of Overall Survival With Gene Expression Profiles in a Prospective Study of Resectable Esophageal Cancer
Sheela Rao , Lyndsey Welsh , David Cunningham , Robert H. te-Poele
Clinical Colorectal Cancer 10 ( 1) 48 -56
10
2011
The kinase polypharmacology landscape of clinical PARP inhibitors.
Albert A. Antolin , Malaka Ameratunga , Udai Banerji , Paul A. Clarke
Scientific Reports 10 ( 1) 2585
19
2020
Labeling and Purification of RNA Synthesized by In Vitro Transcription
Paul A. Clarke
RNA-Protein Interaction Protocols 118 1 -10
14
1999
RNA Footprinting and Modification Interference Analysis
Paul A. Clarke
RNA-Protein Interaction Protocols 118 73 -91
21
1999
Small-molecule targeting of brachyury transcription factor addiction in chordoma.
Tanaz Sharifnia , Mathias J. Wawer , Ting Chen , Qing-Yuan Huang
Nature Medicine 25 ( 2) 292 -300
43
2019
Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor
Steven R. Whittaker , Clare Barlow , Mathew P. Martin , Caterina Mancusi
Molecular Oncology 12 ( 3) 287 -304
18
2018
Array technology in the molecular pharmacology of anticancer agents
Paul Workman , Katharine E. Pestell , Isabelle Hostein , Alison Maloney
Nature Genetics 23 ( 3) 82 -82
1999
CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells.
Rebecca F. Rogers , Michael I. Walton , Daniel L. Cherry , Ian Collins
Cancer Research 80 ( 8) 1735 -1747
10
2020